Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas.
暂无分享,去创建一个
J. Schlom | H. Cooper | L. Weiner | M. von Mehren | M. Mehren | N. Meropol | K. Tsang | A. Rogatko | P. Arlen | M. Davey | S. Mclaughlin | Neal J. Meropol | S. McLaughlin
[1] J. Schlom,et al. Agonist peptide from a cytotoxic t‐lymphocyte epitope of human carcinoembryonic antigen stimulates production of tc1‐type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide , 2000, International journal of cancer.
[2] E. Gilboa,et al. Induction of carcinoembryonic antigen (cea)‐specific cytotoxic t‐lymphocyte responses In vitro using autologous dendritic cells loaded with cea peptide or cea rna in patients with metastatic malignancies expressing cea , 1999, International journal of cancer.
[3] B. Robinson,et al. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. , 1999, Cancer research.
[4] F. Guadagni,et al. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. , 1999, Cancer research.
[5] M. Hanna,et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial , 1999, The Lancet.
[6] J. Marshall,et al. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] J. Fagerberg,et al. Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen , 1998, Cancer Immunology, Immunotherapy.
[8] J. Schlom,et al. Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[9] J. Schlom,et al. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. , 1997, Cancer research.
[10] D. Carbone,et al. Decreased antigen presentation by dendritic cells in patients with breast cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[11] H. Rammensee,et al. A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[12] D. Curiel,et al. Phase Ia Trial of a Polynucleotide Anti-Tumor Immunization to Human Carcinoembryonic Antigen in Patients with Metastatic Colorectal Cancer. University of Alabama at Birmingham, Birmingham, Alabama , 1996 .
[13] Phase Ia trial of a polynucleotide anti-tumor immunization to human carcinoembryonic antigen in patients with metastatic colorectal cancer. Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama. , 1996, Human gene therapy.
[14] M. Colombo,et al. A B7‐1‐transfected human melanoma line stimulates proliferation and cytotoxicity of autologous and allogeneic lymphocytes , 1995, European journal of immunology.
[15] M. Kieny,et al. Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1 , 1995, Journal of virology.
[16] W. L. Shupert,et al. Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity. , 1995, Cancer research.
[17] J. Schlom,et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. , 1995, Journal of the National Cancer Institute.
[18] R. Siliciano,et al. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene. , 1995, The Journal of infectious diseases.
[19] J. Gribben,et al. B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. , 1995, Immunity.
[20] Laurie H Glimcher,et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy , 1995, Cell.
[21] M. Lee,et al. Concentration and distribution of tumor associated antigens TAG-72 and CEA in stomach cancer , 1995, Annals of nuclear medicine.
[22] J. Simpson,et al. Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients , 1994, Cancer.
[23] C. Janeway,et al. Signals and signs for lymphocyte responses , 1994, Cell.
[24] Chen-feng Qi,et al. Definition of the expression of the human carcinoembryonic antigen and non‐specific cross‐reacting antigen in human breast and lung carcinomas , 2009, International journal of cancer.
[25] G. Freeman,et al. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[26] E. Jaffee,et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[27] E. Paoletti,et al. Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL , 1993, Journal of virology.
[28] T. Whiteside,et al. T cell recognition of human tumors: implications for molecular immunotherapy of cancer. , 1993, Clinical immunology and immunopathology.
[29] J. Allison,et al. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. , 1993, Science.
[30] P. Linsley,et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 , 1992, Cell.
[31] E. Paoletti,et al. Immunisation with canarypox virus expressing rabies glycoprotein , 1992, The Lancet.
[32] E. Paoletti,et al. Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins. , 1992, Virology.
[33] J. Holmgren,et al. Coexpression of ganglioside antigen Fuc-GM1, neural-cell adhesion molecule, carcinoembryonic antigen, and carbohydrate tumor-associated antigen CA 50 in lung cancer. , 1992, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.
[34] E. Paoletti,et al. Efficacy studies on a canarypox-rabies recombinant virus. , 1991, Vaccine.
[35] W. Zimmermann,et al. Chromosomal localization of the carcinoembryonic antigen gene family and differential expression in various tumors. , 1988, Cancer research.
[36] W. Zimmermann,et al. The carcinoembryonic antigen gene family: structure, expression and evolution. , 1988, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.
[37] J. Lundy,et al. Definition by monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinomas versus normal adult tissues. , 1985, Cancer research.
[38] J. Beatty,et al. CEA-related antigens: molecular biology and clinical significance. , 1985, Critical reviews in oncology/hematology.
[39] C. Wagener,et al. Binding of five monoclonal anti‐CEA antibodies with different epitope specifities to various carcinoma tissues , 1984, International journal of cancer.
[40] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.
[41] J. Shuster,et al. Carcinoembryonic antigen (CEA): molecular biology and clinical significance. , 1975, Biochimica et biophysica acta.
[42] Phil Gold,et al. DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES , 1965, The Journal of experimental medicine.